HH-009 is under clinical development by Huahui Anjian (Beijing) Biotechnology and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HH-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HH-009 overview

HH-009 is under development for the treatment of solid tumors including metastatic hepatocellular carcinoma (HCC), gastric adenocarcinoma/esophagogastric junction adenocarcinoma, metastatic colorectal cancer. The drug candidate is administered through intravenous route.

Huahui Anjian (Beijing) Biotechnology overview

Huahui Anjian (Beijing) Biotechnology is a pharmaceutical company which is involved in research and development of medical drugs. The company is headquartered in Bejing, China.

For a complete picture of HH-009’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.